These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

469 related items for PubMed ID: 23692505

  • 1. Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion.
    Uhlmann EJ, Shenoy S, Goodnough LT.
    Transfusion; 2014 Feb; 54(2):384-8. PubMed ID: 23692505
    [Abstract] [Full Text] [Related]

  • 2. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease.
    Talano JA, Hillery CA, Gottschall JL, Baylerian DM, Scott JP.
    Pediatrics; 2003 Jun; 111(6 Pt 1):e661-5. PubMed ID: 12777582
    [Abstract] [Full Text] [Related]

  • 3. Hyperhemolytic transfusion reaction attributable to anti-Fy3 in a patient with sickle cell disease.
    Reyes MA, Illoh OC.
    Immunohematology; 2008 Jun; 24(2):45-51. PubMed ID: 19852130
    [Abstract] [Full Text] [Related]

  • 4. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab.
    Gupta S, Fenves A, Nance ST, Sykes DB, Dzik WS.
    Transfusion; 2015 Mar; 55(3):623-8. PubMed ID: 25257194
    [Abstract] [Full Text] [Related]

  • 5. Hyperhemolysis syndrome in patients with sickle cell anemia: report of three cases.
    Santos B, Portugal R, Nogueira C, Loureiro M.
    Transfusion; 2015 Jun; 55(6 Pt 2):1394-8. PubMed ID: 25677578
    [Abstract] [Full Text] [Related]

  • 6. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review.
    Win N, New H, Lee E, de la Fuente J.
    Transfusion; 2008 Jun; 48(6):1231-8. PubMed ID: 18373500
    [Abstract] [Full Text] [Related]

  • 7. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease.
    Noizat-Pirenne F, Bachir D, Chadebech P, Michel M, Plonquet A, Lecron JC, Galactéros F, Bierling P.
    Haematologica; 2007 Dec; 92(12):e132-5. PubMed ID: 18055978
    [Abstract] [Full Text] [Related]

  • 8. Autoantibody formation after alloimmunization inducing bystander immune hemolysis.
    Mota M, Bley C, Aravechia MG, Hamerschlak N, Sakashita A, Kutner JM, Castiho L.
    Immunohematology; 2009 Dec; 25(1):9-12. PubMed ID: 19856726
    [Abstract] [Full Text] [Related]

  • 9. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death.
    Chadebech P, Habibi A, Nzouakou R, Bachir D, Meunier-Costes N, Bonin P, Rodet M, Chami B, Galacteros F, Bierling P, Noizat-Pirenne F.
    Transfusion; 2009 Sep; 49(9):1785-92. PubMed ID: 19413729
    [Abstract] [Full Text] [Related]

  • 10. Transfusion of multiple units of Js(b+) red blood cells in the presence of anti-Jsb in a patient with sickle beta-thalassemia disease and a review of the literature.
    Yuan S, Ewing NP, Bailey D, Salvador M, Wang S.
    Immunohematology; 2007 Sep; 23(2):75-80. PubMed ID: 18004938
    [Abstract] [Full Text] [Related]

  • 11. Lower alloimmunization rates in pediatric sickle cell patients on chronic erythrocytapheresis compared to chronic simple transfusions.
    Wahl SK, Garcia A, Hagar W, Gildengorin G, Quirolo K, Vichinsky E.
    Transfusion; 2012 Dec; 52(12):2671-6. PubMed ID: 22519830
    [Abstract] [Full Text] [Related]

  • 12. Challenges in preventing and treating hemolytic complications associated with red blood cell transfusion.
    Chonat S, Arthur CM, Zerra PE, Maier CL, Jajosky RP, Yee MEM, Miller MJ, Josephson CD, Roback JD, Fasano R, Stowell SR.
    Transfus Clin Biol; 2019 May; 26(2):130-134. PubMed ID: 30979566
    [Abstract] [Full Text] [Related]

  • 13. Posttransfusion hyperhemolysis is arrested by targeting macrophage activation with novel use of Tocilizumab.
    Lee LE, Beeler BW, Graham BC, Cap AP, Win N, Chen F.
    Transfusion; 2020 Jan; 60(1):30-35. PubMed ID: 31642065
    [Abstract] [Full Text] [Related]

  • 14. Anti-N and anti-Doa immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature.
    Unnikrishnan A, Pelletier JPR, Bari S, Zumberg M, Shahmohamadi A, Spiess BD, Michael MJ, Harris N, Harrell D, Mandernach MW.
    Transfusion; 2019 Jun; 59(6):1907-1910. PubMed ID: 30768787
    [Abstract] [Full Text] [Related]

  • 15. Prevention of potential delayed hemolytic transfusion reaction in two sickle cell patients using intravenous immunoglobulins and steroids before and after red blood cell exchange with antigen positive units and review literature.
    Shold J, Dasgupta A, Ye Z.
    Transfus Apher Sci; 2024 Jun; 63(3):103920. PubMed ID: 38570214
    [Abstract] [Full Text] [Related]

  • 16. Immunoglobulin-resistant delayed hemolytic transfusion reaction treated with rituximab in an adult sickle cell patient.
    Delmonte L, Cantini M, Olivieri O, De Franceschi L.
    Transfusion; 2013 Mar; 53(3):688-9. PubMed ID: 23473065
    [No Abstract] [Full Text] [Related]

  • 17. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.
    Vlachaki E, Gavriilaki E, Kafantari K, Adamidou D, Tsitsikas D, Chasapopoulou E, Anagnostopoulos A, Tsapas A.
    Hemoglobin; 2018 Mar; 42(5-6):339-341. PubMed ID: 30626228
    [Abstract] [Full Text] [Related]

  • 18. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions.
    Aygun B, Padmanabhan S, Paley C, Chandrasekaran V.
    Transfusion; 2002 Jan; 42(1):37-43. PubMed ID: 11896310
    [Abstract] [Full Text] [Related]

  • 19. Acquired hemoglobin variants and exposure to glucose-6-phosphate dehydrogenase deficient red blood cell units during exchange transfusion for sickle cell disease in a patient requiring antigen-matched blood.
    Raciti PM, Francis RO, Spitalnik PF, Schwartz J, Jhang JS.
    J Clin Apher; 2013 Aug; 28(4):325-9. PubMed ID: 23450789
    [Abstract] [Full Text] [Related]

  • 20. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab.
    Boonyasampant M, Weitz IC, Kay B, Boonchalermvichian C, Liebman HA, Shulman IA.
    Transfusion; 2015 Oct; 55(10):2398-403. PubMed ID: 25989361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.